2,3-Di(2-furanyl)benzo[g]quinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-Di(2-furanyl)benzo[g]quinoxaline
• 英文别名: 2,3-bis(furan-2-yl)benzo[g]quinoxaline
• 化学式: C₂₀H₁₂N₂O₂
• 分子量: 312.327
• InChiKey: MTWHFYCTTLPMIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,3-二氨基萘 、 糠偶酰 以 甲醇 为溶剂， 以79 %的产率得到2,3-Di(2-furanyl)benzo[g]quinoxaline
  参考文献：
  名称：

  用于光疗的罗丹明-铱 (III) 混合系统中调节 ROS 性质的配体调控策略

  摘要：

  光动力疗法（PDT）的疗效高度依赖于光敏剂的特性。光敏剂产生的活性氧（ROS）已被证明与免疫治疗相关，可引发免疫原性细胞死亡（ICD）。在这项工作中，我们建立了一种作为光敏剂的罗丹明-铱（III）混合模型，以全面了解其在光动力免疫治疗中的性能和潜在应用。特别是，系统地研究并关联了ROS生成效率与由环金属化（ C∧N ）配体调节的基于Ir（III）的激发态（T 1 '）的能级之间的相关性。我们证明，除了在重 Ir(III) 金属中心的帮助下通过系间穿越过程形成的罗丹明三重态 (T 1 ) 的直接布居之外，微调的 T 1 ' 态还可以充当中继为促进级联能量转移过程提供额外的途径，从而增强ROS生成能力。此外，通过在C∧N配体中引入含硫噻吩单元，可以有效产生I型ROS，在缺氧条件下提供更强的M1巨噬细胞激活效率，从而激发体内抗肿瘤免疫。总的来说，我们的工作为生物医学应用的先进过渡金属光敏剂的分子设计和探索提供了基本指导。

  DOI：

  10.1021/acs.inorgchem.3c04350

文献信息

• [BBSA-DBN][HSO4]: a novel –SO3H functionalized Bronsted acidic ionic liquid for easy access of quinoxalines
  作者：Megha U. Patil、Sachinkumar K. Shinde、Sandip P. Patil、Suresh S. Patil

  DOI：10.1007/s11164-020-04227-3

  日期：2020.11

  Abstract A novel –SO3H difunctionalized Bronsted acidic ionic liquid (BAIL) 1, 5-bis (butanesulphonic acid)-diazobicyclo [4,3,0] non-5-enium hydrogen sulphate [BBSA-DBN][HSO4] is introduced for efficient synthesis of quinoxalines via condensation of substituted 1,2-diketones and various aromatic 1,2-diamines. It could serve as a dual functional catalyst for these reactions. This method has the advantages

  摘要 新型–SO 3 H双官能化布朗斯台德酸性离子液体（BAIL）1，5-双（丁磺酸）-重氮双环[4,3,0]非-5-氢硫酸氢盐[BBSA-DBN] [HSO 4引入[1]通过取代的1，2-二酮和各种芳族1，2-二胺的缩合有效合成喹喔啉。它可以用作这些反应的双重功能催化剂。该方法的优点是反应条件温和，收率高，反应时间短，后处理容易，非色谱分离，环境友好。该方案为生产喹喔啉提供了一种有效且环保的替代方法，并扩展了有机合成中苯的化学利用。此室温衍生离子液体是高酸性是由于两个-SO的存在3个H基团和两个HSO 4 -的阴离子。此外，IL [BBSA-DBN] [HSO 4可以很容易地被回收并至少重复使用五次而不会改变其催化活性。IL [BBSA-DBN] [HSO 4 ]的形成通过1 H，13 C NMR光谱技术确认。 图形摘要
• Molecular iodine: a powerful catalyst for the easy and efficient synthesis of quinoxalines
  作者：Shivaji V. More、M.N.V. Sastry、Chieh-Chieh Wang、Ching-Fa Yao

  DOI：10.1016/j.tetlet.2005.07.026

  日期：2005.9

  Various biologically important quinoxaline derivatives were efficiently synthesized in excellent yields using inexpensive, nontoxic, and readily available bench top chemical, iodine in catalytic amount (10 mol %). Besides this, a systematic study was carried out to evaluate parameters such as solvent and catalyst loading. Several aromatic as well as aliphatic 1,2-diketones and aromatic 1,2-diamines, such as substituted phenylene diamines, tetra amines were further subjected to condensation using catalytic amounts of iodine to afford the products in excellent yield. (c) 2005 Published by Elsevier Ltd.
• Novel alanyl-amino peptidase inhibitors for functionally influencing different cells and treating immunological, inflammatory, neuronal, and other diseases
  申请人：Ansorge Siegfried

  公开号：US20070037752A1

  公开（公告）日：2007-02-15

  The invention relates to substances which specifically inhibit peptidases splitting ala-p-nitroanilide for use in medicine. The invention further relates to the use of at least one such substance or of a pharmaceutical or cosmetic composition containing at least one such substance for the prophylaxis and therapy of diseases, in particular the prophylaxis and therapy of diseases with an overshooting immune response (autoimmune diseases, allergies and transplant rejections), of other chronic inflammatory diseases, neuronal diseases and brain damages, skin diseases (acne and psoriasis, among others), tumor diseases and special virus infections (including SARS).
• [EN] BENZO[G]QUINOXALINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST INFECTIOUS DISEASES<br/>[FR] DERIVES DE LA BENZO[G]QUINOXALINE COMPOSES EFFICACES CONTRE LES MALADIES INFECTIEUSES
  申请人：AXXIMA PHARMACEUTICALS AG

  公开号：WO2002094796A2

  公开（公告）日：2002-11-28

  The present invention relates to benzo[g]quinoxaline derivatives of the general formula (I), processes for manufacturing said benzo[g]quinoxaline derivatives, the use of the benzo[g]quinoxaline derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases and opportunistic infections, diabetes, cancer, inflammation, as well as compositions containing at least one benzo[g]quinoxaline derivative and/or pharmaceutically acceptable salt thereof. Further, the present invention is directed to methods for preventing and/or treating of infectious diseases, diabetes, cancer, and inflammation using the inventive benzo[g]quinoxaline derivatives.